Menu
Back to Journals » Clinical Ophthalmology » Volume 13
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
Authors Tauber J , Schechter BA, Bacharach J, Toyos MM , Smyth-Medina R, Weiss SL , Luchs JI
Received 15 January 2019
Accepted for publication 15 January 2019
Published 24 January 2019 Volume 2019:13 Pages 215—216
Tauber J, Schechter BA, Bacharach J, et al. Clin Ophthalmol. 2018;12:1921–1929.
On page 1927, “Safety and tolerability assessments” section, third paragraph, first sentence should read from “Fifteen subjects exited the study due to AEs: 5 subjects (3.3%) in the OTX-101 0.09% group, 4 subjects (2.6%) in the OTX-101 0.09% group, and 6 subjects (3.9%) in the vehicle group.” to “Fifteen subjects exited the study due to AEs: 5 subjects (3.3%) in the OTX-101 0.09% group, 4 subjects (2.6%) in the OTX-101 0.05% group, and 6 subjects (3.9%) in the vehicle group.”
Read the original article
Previous corrigendum has been published
© 2019 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.